CDC Logo Skip Top Nav
 CDC Home PageSearch the CDCHealth Topics A though Z
Skip
Division of Tuberculosis Elimination
About DTBE Upcoming Events Site Map CDC en Espanol Contact Us
 
Skip the Contents menu

Contents

Skip the Resources menu

Resources



U.S. Department of Health and Human Services
 
 

Mantoux Tuberculosis Skin Test Facilitator Guide

Return to Mantoux TB Skin Test Facilitator Guide Main Page

Appendix D: Mantoux Tuberculin Skin Test Interpretation Table

Skin test interpretation depends on

(1) the measurement in millimeters (mm) of the induration and
(2) the person's risk of being infected with TB and/ or progression to disease if infected.

The following three cut points should be used to determine whether the skin test reaction is positive. A measurement of 0 mm or anything below the defined cut point for each category is considered negative.

Induration of ³ 5 mm is considered positive in
Induration of ³ 10 mm is considered positive in
Induration of ³ 15 mm is considered positive in
  • Human immunodeficiency virus (HIV)-positive persons
  • Recent contacts of TB case patients
  • Persons with fibrotic changes on chest radiograph consistent with prior TB
  • Patients with organ transplants and other immunosuppressed patients (Receiving the equivalent of ³15 mg/d of prednisone for 1 month or more Risk of TB in patients with corticosteroids increases with higher dose and longer duration.)
  • Recent immigrants (i.e., within the last 5 years) from high-prevalence countries
  • Injection drug users
  • Residents and employees† of the following high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with acquired immunodeficiency syndrome (AIDS), and homeless shelters
  • Mycobacteriology laboratory personnel
  • Persons with the following clinical conditions that place them at high risk: silicosis, diabetes mellitus, chronic renal failure, some hematologic disorders (e.g., leukemias and lymphomas), other specific malignancies (e.g., carcinoma of the head, neck, or lung),weight loss of ³10% of ideal body weight, gastrectomy, and jejunoileal bypass
  • Children < 4 years of age, or infants, children and adolescents exposed to adults at high-risk
  • Persons with no known risk factors for TB
  • † For persons who are otherwise at low risk for TB and who are tested at the start of employment, a reaction of ³15 mm is considered positive.

    Last Reviewed: 05/18/2008
    Content Source: Division of Tuberculosis Elimination
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

     

     
    Back to Top of Page


    If you would like to order any of the DTBE publications please visit the online order form.

    You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

    If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

    Division of Tuberculosis Elimination
    Attn: Content Manager, DTBE Web site
    Centers for Disease Control and Prevention
    1600 Clifton Rd., NE Mailstop E-10
    Atlanta, GA 30333
    CDC-INFO at (1-800) 232-4636
    TTY: 1 (888) 232-6348
    E-mail: cdcinfo@cdc.gov


    Skip Bottom Nav Home | Site Map | Contact Us
    Accessibility | Privacy Policy Notice | FOIA | USA.gov
    CDC Home | Search | Health Topics A-Z

    Centers for Disease Control & Prevention
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
    Division of Tuberculosis Elimination
    Please send comments/suggestions/requests to: CDCINFO@cdc.gov